Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18163387 | 0.91 | MET (0.56) | METIGF1RKDRCSF1RSYK | |
| SCHEMBL23456977 | 0.85 | MET (0.56) | METIGF1RKDRCSF1RSYK | |
| SCHEMBL18163443 | 0.83 | MET (0.60) | METIGF1RKDRSYKPTK2 | |
| SCHEMBL23456887 | 0.82 | MET (0.57) | METIGF1RKDRCSF1RSYK | |
| SCHEMBL23456891 | 0.82 | MET (0.57) | METIGF1RKDRCSF1RSYK | |
| Adrixetinib SCHEMBL23456979 | 0.82 | MET (0.59) | METIGF1RKDRCSF1RSYK | |
| Adrixetinib SCHEMBL31614098 | 0.82 | MET (0.59) | METIGF1RKDRCSF1RSYK | |
| SCHEMBL23457013 | 0.82 | MET (0.56) | METIGF1RKDRCSF1RSYK | |
| SCHEMBL23457035 | 0.82 | MET (0.60) | METIGF1RKDRCSF1RSYK | |
| SCHEMBL23456819 | 0.81 | MET (0.58) | METIGF1RKDRCSF1RPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | TYRO3, MERTK, AXL | MET 5/4885IGF1R 145/4885KDR 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.